Result of General Meeting
Biodexa Pharmaceuticals (Nasdaq: BDRX) held a General Meeting on May 2, 2025, where two ordinary resolutions received majority votes of 62% and 61%. However, a crucial special resolution (Resolution 3) failed to pass, receiving 71% of votes when it needed 75%. Since Resolution 1 was dependent on Resolution 3's approval, it also failed despite its majority vote. The failed Resolution 3 was aimed at reducing the nominal value of shares to provide more flexibility in future fundraising efforts. The company's Chairman, Dr. Stephen Parker, indicated that alternative proposals will be presented in the future.
Biodexa Pharmaceuticals (Nasdaq: BDRX) ha tenuto un'Assemblea Generale il 2 maggio 2025, durante la quale due delibere ordinarie hanno ottenuto la maggioranza dei voti, rispettivamente il 62% e il 61%. Tuttavia, una delibera speciale cruciale (Delibera 3) non è stata approvata, ricevendo il 71% dei voti a fronte del 75% necessario. Poiché la Delibera 1 dipendeva dall'approvazione della Delibera 3, anche questa è fallita nonostante la maggioranza dei voti. La Delibera 3 mirava a ridurre il valore nominale delle azioni per offrire maggiore flessibilità nelle future raccolte di fondi. Il Presidente della società, il Dr. Stephen Parker, ha indicato che in futuro saranno presentate proposte alternative.
Biodexa Pharmaceuticals (Nasdaq: BDRX) celebró una Asamblea General el 2 de mayo de 2025, donde dos resoluciones ordinarias obtuvieron la mayoría de votos, con un 62% y un 61% respectivamente. Sin embargo, una resolución especial crucial (Resolución 3) no fue aprobada, recibiendo un 71% de los votos cuando necesitaba un 75%. Dado que la Resolución 1 dependía de la aprobación de la Resolución 3, también falló a pesar de tener mayoría. La Resolución 3 buscaba reducir el valor nominal de las acciones para proporcionar mayor flexibilidad en futuras rondas de financiación. El presidente de la compañía, el Dr. Stephen Parker, indicó que se presentarán propuestas alternativas en el futuro.
Biodexa Pharmaceuticals (나스닥: BDRX)는 2025년 5월 2일 총회를 개최했으며, 두 건의 일반 결의안이 각각 62%와 61%의 찬성표를 얻었습니다. 그러나 중요한 특별 결의안(결의안 3)은 75%의 찬성 필요 기준을 충족하지 못하고 71%의 찬성표만 받으며 부결되었습니다. 결의안 1은 결의안 3의 승인에 의존했기 때문에 다수 찬성에도 불구하고 실패했습니다. 결의안 3은 주식의 액면가를 낮춰 향후 자금 조달에 더 큰 유연성을 제공하려는 목적이었습니다. 회사 회장인 스티븐 파커 박사는 앞으로 대체 제안이 제시될 것이라고 밝혔습니다.
Biodexa Pharmaceuticals (Nasdaq : BDRX) a tenu une Assemblée Générale le 2 mai 2025, où deux résolutions ordinaires ont obtenu la majorité des voix, respectivement 62 % et 61 %. Cependant, une résolution spéciale cruciale (Résolution 3) n’a pas été adoptée, recevant 71 % des votes alors qu’elle nécessitait 75 %. Étant donné que la Résolution 1 dépendait de l’approbation de la Résolution 3, elle a également échoué malgré sa majorité. La Résolution 3 visait à réduire la valeur nominale des actions afin de permettre une plus grande flexibilité lors des futures levées de fonds. Le président de la société, Dr Stephen Parker, a indiqué que des propositions alternatives seront présentées à l’avenir.
Biodexa Pharmaceuticals (Nasdaq: BDRX) hielt am 2. Mai 2025 eine Hauptversammlung ab, bei der zwei ordentliche Beschlüsse mit Mehrheiten von 62% und 61% angenommen wurden. Ein wichtiger Sonderbeschluss (Beschluss 3) wurde jedoch nicht angenommen, da er 71% der Stimmen erhielt, aber 75% benötigt hätte. Da Beschluss 1 von der Zustimmung zu Beschluss 3 abhängig war, scheiterte auch dieser trotz der Mehrheit. Beschluss 3 zielte darauf ab, den Nennwert der Aktien zu senken, um zukünftige Kapitalbeschaffungen flexibler zu gestalten. Der Vorsitzende des Unternehmens, Dr. Stephen Parker, kündigte an, dass künftig alternative Vorschläge vorgelegt werden.
- None.
- Failed to pass special resolution needed for share restructuring, limiting company's flexibility for future fundraising
May 2, 2025
Biodexa Pharmaceuticals PLC
(“Biodexa” or the “Company”)
Result of General Meeting
Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announces that at its General Meeting held at 1.00pm BST today, ordinary resolutions 1 and 2 were passed by majorities of
Commenting, Dr. Stephen Parker, Chairman of Biodexa said “It is unfortunate that resolution 3 failed to pass by
o0o
About Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. The Company’s lead development programs include eRapa, under development for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer; tolimidone, under development for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications.
eRapa is a proprietary oral tablet formulation of rapamycin, also known as sirolimus. Rapamycin is an mTOR (mammalian Target Of Rapamycin) inhibitor. mTOR has been shown to have a significant role in the signalling pathway that regulates cellular metabolism, growth and proliferation and is activated during tumorigenesis.
Tolimidone is an orally delivered, potent and selective inhibitor of Lyn kinase. Lyn is a member of the Src family of protein tyrosine kinases, which is mainly expressed in hematopoietic cells, in neural tissues, liver, and adipose tissue. Tolimidone demonstrates glycaemic control via insulin sensitization in animal models of diabetes and has the potential to become a first in class blood glucose modulating agent.
MTX110 is a solubilized formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at chemotherapeutic doses directly to the site of the tumor, by-passing the blood-brain barrier and potentially avoiding systemic toxicity.
Biodexa is supported by three proprietary drug delivery technologies focused on improving the bio-delivery and bio-distribution of medicines. Biodexa’s headquarters and R&D facility is in Cardiff, UK. For more information visit www.biodexapharma.com.
Forward-Looking Statements
Certain statements in this announcement may constitute “forward-looking statements” within the meaning of legislation in the United Kingdom and/or United States. Such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are based on management’s belief or interpretation. All statements contained in this announcement that do not relate to matters of historical fact should be considered forward-looking statements. In certain cases, forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved.” Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause their actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein.
Reference should be made to those documents that Biodexa shall file from time to time or announcements that may be made by Biodexa in accordance with the rules and regulations promulgated by the SEC, which contain and identify other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Biodexa are expressly qualified in their entirety by the cautionary statements above. Except as may be required under relevant laws in the United States, Biodexa does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or events otherwise arising.
FAQ
What happened at Biodexa Pharmaceuticals (BDRX) General Meeting on May 2, 2025?
Why did Resolution 3 fail at BDRX's General Meeting?
What was the purpose of Resolution 3 for Biodexa Pharmaceuticals?
What is Biodexa's (BDRX) plan after the failed resolution?
